Refine
Has Fulltext
- yes (13)
Is part of the Bibliography
- yes (13)
Year of publication
- 2013 (13) (remove)
Document Type
- Journal article (13) (remove)
Language
- English (13) (remove)
Keywords
- cell staining (3)
- T cells (2)
- allogeneic stem cell transplantation (2)
- multiple myeloma (2)
- Allogeneic stem cell transplantation (1)
- Antibodies (1)
- B cells (1)
- Bioluminescence (1)
- Bioluminescence imaging (1)
- Bone marrow cells (1)
- Bone marrow transplantation (1)
- Cancer treatment (1)
- GUT-directed hypnotherapy (1)
- GVHD (1)
- GVL (1)
- Graft-versus-host disease (1)
- HLA antigens (1)
- HT29 cells (1)
- Haematology (1)
- Infectious Diseases (1)
- Lymphomas (1)
- Minor histocompatibility antigen mismatch transplantation (1)
- Myeloma cells (1)
- Myelomas (1)
- Positron emission tomography (1)
- Spleen (1)
- T cell (1)
- amyloidosis (1)
- apoptosis (1)
- biosynthesis (1)
- bone marrow cells (1)
- bone marrow transplantation (1)
- cancer treatment (1)
- cardiac transplantation (1)
- cell binding (1)
- cell death (1)
- cell viability testing (1)
- cognitive hypnotherapy (1)
- complement system (1)
- cytokines (1)
- cytotoxicity (1)
- deformation (1)
- echocardiography (1)
- ejection fraction (1)
- electrogastrographic egg activities (1)
- enzyme-linked immunoassays (1)
- functional abdominal pain (1)
- fungi (1)
- gastrointestinal symptoms (1)
- hematopoietic (1)
- hypnotic susceptibility (1)
- immune cells (1)
- immune reconstitution (1)
- immunohistochemistry techniques (1)
- irritable-bowle-sondrome (1)
- lesions (1)
- leukemia (1)
- metastasis (1)
- mismatch (1)
- necrotic cell death (1)
- phosphorylation (1)
- prognosis (1)
- rectal sensitivity (1)
- regression analysis (1)
- regulatory T cells (1)
- respiratory virus (1)
- signal inhibition (1)
- small interfering RNAs (1)
- stem cell transplantation (1)
- transplantation (1)
- ulcerative colitis (1)
- virus (1)
- virus-specific T-cell (1)
- water load test (1)
Institute
- Medizinische Klinik und Poliklinik II (13) (remove)
Sonstige beteiligte Institutionen
Community-acquired respiratory virus (CARV) infections have been recognized as a significant cause of morbidity and mortality in patients with leukemia and those undergoing hematopoietic stem cell transplantation (HSCT). Progression to lower respiratory tract infection with clinical and radiological signs of pneumonia and respiratory failure appears to depend on the intrinsic virulence of the specific CARV as well as factors specific to the patient, the underlying disease, and its treatment. To better define the current state of knowledge of CARVs in leukemia and HSCT patients, and to improve CARV diagnosis and management, a working group of the Fourth European Conference on Infections in Leukaemia (ECIL-4) 2011 reviewed the literature on CARVs, graded the available quality of evidence, and made recommendations according to the Infectious Diseases Society of America grading system. Owing to differences in screening, clinical presentation, and therapy for influenza and adenovirus, ECIL-4 recommendations are summarized for CARVs other than influenza and adenovirus.
Immune reconstitution of functional virus-specific T cells after allogeneic hematopoietic stem cell transplantation (HSCT) has been intensively investigated. However, the possible role of crossreactivity of these virus-specific T cells against allogeneic targets is still unclear. Theoretically, as in the field of organ transplantation, virus-specific T cells possess crossreactivity potential after allogeneic HSCT. Such crossreactivity is assumed to play a role in graft-versus-host disease and graft-versus-leukemia effects. In this article, we aim to give a comprehensive overview of current understanding about crossreactivity of virus-specific T cells.
Background
Acute graft-versus-host disease (aGVHD) poses a major limitation for broader therapeutic application of allogeneic hematopoietic cell transplantation (allo-HCT). Early diagnosis of aGVHD remains difficult and is based on clinical symptoms and histopathological evaluation of tissue biopsies. Thus, current aGVHD diagnosis is limited to patients with established disease manifestation. Therefore, for improved disease prevention it is important to develop predictive assays to identify patients at risk of developing aGVHD. Here we address whether insights into the timing of the aGVHD initiation and effector phases could allow for the detection of migrating alloreactive T cells before clinical aGVHD onset to permit for efficient therapeutic intervention.
Methods
Murine major histocompatibility complex (MHC) mismatched and minor histocompatibility antigen (miHAg) mismatched allo-HCT models were employed to assess the spatiotemporal distribution of donor T cells with flow cytometry and in vivo bioluminescence imaging (BLI). Daily flow cytometry analysis of peripheral blood mononuclear cells allowed us to identify migrating alloreactive T cells based on homing receptor expression profiles.
Results
We identified a time period of 2 weeks of massive alloreactive donor T cell migration in the blood after miHAg mismatch allo-HCT before clinical aGVHD symptoms appeared. Alloreactive T cells upregulated α4β7 integrin and P-selectin ligand during this migration phase. Consequently, targeted preemptive treatment with rapamycin, starting at the earliest detection time of alloreactive donor T cells in the peripheral blood, prevented lethal aGVHD.
Conclusions
Based on this data we propose a critical time frame prior to the onset of aGVHD symptoms to identify alloreactive T cells in the peripheral blood for timely and effective therapeutic intervention.